Terms: = Lung cancer AND SMARCA4, hSNF2b, 6597, P51532, BRG1, SNF2L4, SNF2, SWI2, FLJ39786, BAF190, SNF2LB, SNF2-BETA, ENSG00000127616 AND Treatment
74 results:
1. Redox
Wei XW; Lu C; Zhang YC; Fan X; Xu CR; Chen ZH; Wang F; Yang XR; Deng JY; Yang MY; Gou Q; Mei SQ; Luo WC; Zhong RW; Zhong WZ; Yang JJ; Zhang XC; Tu HY; Wu YL; Zhou Q
Oncoimmunology; 2024; 13(1):2340154. PubMed ID: 38601319
[TBL] [Abstract] [Full Text] [Related]
2. [Clinical characteristics and prognosis analysis of 17 cases of smarca4-deficient chest tumors].
Cao XN; Li Z; Wang QY
Zhonghua Jie He He Hu Xi Za Zhi; 2024 Apr; 47(4):325-331. PubMed ID: 38599807
[No Abstract] [Full Text] [Related]
3. treatment of Thoracic smarca4-Deficient Undifferentiated Tumors: Where We Are and Where We Will Go.
Longo V; Catino A; Montrone M; Montagna ES; Pesola F; Marech I; Pizzutilo P; Nardone A; Perrone A; Gesualdo M; Galetta D
Int J Mol Sci; 2024 Mar; 25(6):. PubMed ID: 38542211
[TBL] [Abstract] [Full Text] [Related]
4. smarca4 deficiency and mutations are frequent in large cell lung carcinoma and are prognostically significant.
Cheung AH; Wong KY; Chau SL; Xie F; Mui Z; Li GY; Li MSC; Tong J; Ng CS; Mok TS; Kang W; To KF
Pathology; 2024 Jun; 56(4):504-515. PubMed ID: 38413251
[TBL] [Abstract] [Full Text] [Related]
5. Efficacy of immune checkpoint inhibitors in smarca4-deficient and TP53 mutant undifferentiated lung cancer.
Chen J; Zheng Q; Wang J; Zhang X; Lv Y
Medicine (Baltimore); 2024 Feb; 103(8):e36959. PubMed ID: 38394494
[TBL] [Abstract] [Full Text] [Related]
6. An aggressive case of a thoracic undifferentiated smarca4-deficient tumor with extensive pleural involvement.
Hanona PF; Ezekwudo D; Fullmer J; Allen T; Jaiyesimi I
Thorac Cancer; 2024 Apr; 15(10):847-851. PubMed ID: 38390699
[TBL] [Abstract] [Full Text] [Related]
7. The golden key to open mystery boxes of smarca4-deficient undifferentiated thoracic tumor: focusing immunotherapy, tumor microenvironment and epigenetic regulation.
Li X; Tian S; Shi H; Ta N; Ni X; Bai C; Zhu Z; Chen Y; Shi D; Huang H; Chen L; Hu Z; Qu L; Fang Y; Bai C
Cancer Gene Ther; 2024 May; 31(5):687-697. PubMed ID: 38347129
[TBL] [Abstract] [Full Text] [Related]
8. Thoracic smarca4-deficient undifferentiated tumor: A clinicopathological and prognostic analysis of 35 cases and immunotherapy efficacy.
Zhou P; Fu Y; Tang Y; Jiang L; Wang W
Lung Cancer; 2024 Mar; 189():107471. PubMed ID: 38306886
[TBL] [Abstract] [Full Text] [Related]
9. [Cytopathological characteristics of smarca4-deficient thoracic undifferentiated tumors in serous effusion].
Wang WN; Liu XT; Liang YM
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
[No Abstract] [Full Text] [Related]
10. Molecular and Pathologic Characterization of YAP1-Expressing Small Cell lung cancer Cell Lines Leads to Reclassification as smarca4-Deficient Malignancies.
Ng J; Cai L; Girard L; Prall OWJ; Rajan N; Khoo C; Batrouney A; Byrne DJ; Boyd DK; Kersbergen AJ; Christie M; Minna JD; Burr ML; Sutherland KD
Clin Cancer Res; 2024 May; 30(9):1846-1858. PubMed ID: 38180245
[TBL] [Abstract] [Full Text] [Related]
11. Real-World comprehensive genomic profiling data for diagnostic clarity in pulmonary Large-Cell neuroendocrine carcinoma.
Burns L; Tukachinsky H; Raskina K; Huang RSP; Schrock AB; Sands J; Kulke MH; Oxnard GR; Tapan U
Lung Cancer; 2024 Feb; 188():107454. PubMed ID: 38159439
[TBL] [Abstract] [Full Text] [Related]
12. Thoracic smarca4-deficient undifferentiated tumor: current knowledge and future perspectives.
Shinno Y; Ohe Y;
Jpn J Clin Oncol; 2024 Mar; 54(3):265-270. PubMed ID: 38117955
[TBL] [Abstract] [Full Text] [Related]
13. [Evaluation of Efficacy and Prognosis Analysis of Stage III-IV smarca4-deficient
Non-small Cell lung cancer Treated by PD-1 Immune Checkpoint Inhibitors plus
Chemotherapy and Chemotherapy].
Wang X; Tu M; Jia H; Liu H; Wang Y; Wang Y; Jiang N; Lu C; Zhang G
Zhongguo Fei Ai Za Zhi; 2023 Sep; 26(9):659-668. PubMed ID: 37985152
[TBL] [Abstract] [Full Text] [Related]
14. Prognostic and predictive impact of molecular tumor burden index in non-small cell lung cancer patients.
Yang F; Tang M; Cui L; Bai J; Yu J; Gao J; Nie X; Li X; Xia X; Yi X; Zhang P; Li L
Thorac Cancer; 2023 Nov; 14(31):3097-3107. PubMed ID: 37724484
[TBL] [Abstract] [Full Text] [Related]
15. Biomarkers-Based Cost-Effectiveness of Toripalimab Plus Chemotherapy for Patients with treatment-Naive Advanced Non-Small Cell lung cancer.
Zhang H; Li L; Feng L; Zhou Z; Zhang X; Feng J; Liu Q
Adv Ther; 2023 Nov; 40(11):4945-4956. PubMed ID: 37715852
[TBL] [Abstract] [Full Text] [Related]
16. [Clinicopathological features and prognosis of smarca4-deficient non-small cell lung carcinoma: an analysis of 127 cases].
Li SL; Wu CY; Zhang LP; Huang Y; Wu W; Zhang W; Hou LK
Zhonghua Bing Li Xue Za Zhi; 2023 Jul; 52(7):665-670. PubMed ID: 37408395
[No Abstract] [Full Text] [Related]
17. Dysregulation of SWI/SNF Chromatin Remodelers in NSCLC: Its Influence on cancer Therapies including Immunotherapy.
Shi Y; Shin DS
Biomolecules; 2023 Jun; 13(6):. PubMed ID: 37371564
[TBL] [Abstract] [Full Text] [Related]
18. Mutational landscape of SWI/SNF complex genes reveal correlation to predictive biomarkers for immunotherapy sensitivity in lung adenocarcinoma patients.
Xu H; Chen HC; Yang L; Yang G; Liang L; Yang Y; Tang H; Bao H; Wu X; Shao Y; An G; Wang Y
ESMO Open; 2023 Jun; 8(3):101585. PubMed ID: 37327699
[TBL] [Abstract] [Full Text] [Related]
19. Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma.
Boiarsky D; Lydon CA; Chambers ES; Sholl LM; Nishino M; Skoulidis F; Heymach JV; Luo J; Awad MA; Janne PA; Van Allen EM; Barbie DA; Vokes NI
Ann Oncol; 2023 Jul; 34(7):589-604. PubMed ID: 37121400
[TBL] [Abstract] [Full Text] [Related]
20. Promising efficacy of immune checkpoint inhibitor plus chemotherapy for thoracic smarca4-deficient undifferentiated tumor.
Lin Y; Yu B; Sun H; Zhang H; Hu Z; Zhang Y; Wu Z; Sun S; Zhao X; Yu H; Wu X; Li Y; Wang J; Wang H
J Cancer Res Clin Oncol; 2023 Sep; 149(11):8663-8671. PubMed ID: 37115272
[TBL] [Abstract] [Full Text] [Related]
[Next]
